Skip to main content
Egyptian Liver Journal

Table 3 Comparison between demographic, clinical characteristics, and laboratory data of adults ≥ 60 years and adults < 60 years old patients

From: Impact of treating chronic hepatitis C with direct acting antivirals on health-related quality of life: a real-life Egyptian experience

Baseline characteristics

n = 399

n (%) for categorical values

OR for categorical values

(95% CI)

P value

Mean (SD) for continuous variables

RR for continuous values (95% CI)

P value

Adults < 60 years

(n = 211)

Adults ≥ 60 years

(n = 188)

Adults < 60 years

(n = 211)

Adults ≥ 60 years

(n = 188)

Age (years)

    

41 (10.8)

65 (3.6)

  

Age (years) n = 399

 Adults < 60

211 (53)

188 (47)

      

 Adults ≥ 60

        

Gender

 Male

107 (51)

55 (29)

2.5 (1.6–3.7)

< 0.001

    

 Female

104 (49)

133 (71)

      

Comorbidity: hypertension

  

7.1 (3.8–13.3)

< 0.001

    

 No

197 (93)

124 (66)

      

 Yes

14 (7)

63 (34)

      

Comorbidity: diabetes

  

1.1 (0.7–1.7)

0.76

    

 No

163 (77)

142 (76)

      

 Yes

48 (23)

45 (24)

      

 Missing

0

1

      

BMI (kg/m2)

 Missing

    

29.8 (6.1)

109

31.4 (6.5)

95

1.4 (1.1–1.9)

< 0.01

Comorbidity: obesity (BMI ≥ 30)

 No

76 (75)

46 (50)

2.3 (1.6–5.5)

< 0.001

    

 Yes

26 (25)

47 (51)

      

 Missing

109

95

      

Smoking status

 Smokers

176 (83)

63 (81)

1.1 (0.6–2.2)

0.75

    

 Non-smokers

35 (17)

15 (19)

      

 Missing

0

110

      

Hepatic condition (based on clinician’s decision)

 Normal

80 (38)

27 (26)

3.3 (1.8–6.0)

< 0.001

    

 Abnormal

114 (54)

119 (59)

      

 Cirrhotic

17 (8)

42 (15)

      

FIB-4

 Missing

    

2.31 (1.9)

1

 

2.1 (1.7, 2.5)

< 0.001

FIB-4 (Indicator of cirrhosis)

 < 3.25 (IU)

193 (92)

121 (64)

6.2 (3.5–11.2)

< 0.001

    

 ≥ 3.25 (IU)

17 (8)

67 (36)

      

 Missing

1

0

      

Platelet count (× 109/L)

    

216.4 (68.6)

182.9 (65.9)

1.6 (1.4, 2.0)

< 0.001

Thrombocytopenia

 No (platelet count × 1000/L ≥ 150)

184 (87)

132 (70)

2.9 (1.7–4.8)

< 0.001

    

 Yes (platelet count × 1000/L < 150)

27 (13)

56 (30)

      

HCV serum concentration

 (IU/mL × 10e + 06)

    

2.1 (5.4)

2.0 (6.1))

  

Alfa Feto-protein (10 ng/mL)

        

 Missing

    

10.2 (15.7)

3

5.9 (8.4)

2

1.4 (1.1, 1.7)

0.005

Alfa Feto-protein

 < 10 ng/mL

176 (85)

138 (74)

1.9 (1.2–3.2)

< 0.01

    

 ≥ 10 ng/mL

32 (15)

48 (26)

      

 Missing

3

2

      

Liver enzymes: AST

 (IU/L)

    

44.2 (27.3)

53.2 (35.5)

1.3 (1.0, 1.6)

0.01

Liver enzymes: AST

 Normal level (< 40 IU/L)

121 (57)

85 (45)

1.6 (1.1–2.4)

< 0.01

    

 Abnormal level (≥ 40 IU/L)

90 (43)

103 (55)

      

Liver enzymes: ALT

  (IU/L)

    

49.5 (35.4)

49.8 (35.7)

0.9 (0.8, 1.2)

0.66

Liver enzymes: ALT

 Normal level (< 56 IU/L)

148 (70)

135 (72)

0.9 (0.6–1.4)

0.71

    

 Abnormal level (≥ 56 IU/L)

63 (30)

53 (28)

      

Treatment status

 Naïve

194 (92)

182 (97)

3.3 (1.9–5.9)

< 0.001

    

 Experienced

17 (8)

6 (3)

      

Ribavirin in treatment combination

 No

151 (72)

175 (93)

0.2 (0.1–0.4)

< 0.001

    

 Yes

60 (28)

13 (7)

      
  1. To evaluate the effect of the various demographic and clinical characteristics among adults ≥ 60 years and adults < 60 years, Z-test for odds ratio (OR, 95% CI) was used for the categorical variables to compare demographic and clinical characteristics among adults ≥ 60 years and adults < 60 years old patients, while Z-test for risk ratio (RR, 95% CI) was used for the categorical variables. A value of P < 0.05 was considered to be significant
Back to article page